poisar

Stocks · News reference

Arcturus Therapeutics shares are trading higher. The company announced it will present data on ARCT-810 mRNA therapy in Ornithine Transcarbamylase Deficiency at the 2026 SSIEM Annual Symposium.

Aug 25, 2026, 4:24 PMBenzinga Newsdesk
Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ARCT
Source
benzinga
Observed
Aug 25, 2026, 4:24 PM
Checked
Aug 25, 2026, 4:24 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 1:46 PMResearchandmarkets.Com

    mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

    The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

    Read original at globenewswire-inc
    MRNABNTXARCT